스마트 콘택트렌즈 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the smart contact lenses market size is expected to grow from USD 5.14 million in 2025 to USD 5.52 million in 2026 and is forecast to reach USD 7.88 million by 2031 at 7.39% CAGR over 2026-2031.

This report is Segmented by Application (Ocular Monitoring & Glaucoma Treatment, Vision Impairment), by End User (Hospitals & Ophthalmology Clinics, Home-care/Self-monitoring Consumers, Others), and Geography (North America, Europe, Asia-Pacific, Rest of the World). The Market Forecasts are Provided in Terms of Value (USD).

Global Smart Contact Lenses Market Trends and Insights

Miniaturised On-Lens Biosensors Reach Sub-µW Power Levels

Sub-µW biosensors now harvest ~150 µW at 3.3 V from combined flexible solar and metal-air sources, allowing autonomous operation without bulky battery packs. Ti3C2Tx MXene sensors demonstrate 12.52 mV/mmHg sensitivity for IOP, validating high-accuracy ocular measurements with minimal irritation. This leap enables a shift from research prototypes to commercial devices capable of continuous glucose monitoring, a use-case that commands the largest share of the smart contact lenses market. Lower power budgets also simplify thermal management, preserving corneal comfort during extended wear. Collectively, these advances convert a core technical bottleneck into a launchpad for multi-sensor product roadmaps.

Reimbursement Codes Emerging for IOP & Glucose Tear Monitoring

In 2025, Medicare issued a category III CPT code for continuous tear glucose monitoring, greatly improving provider economics in the United States. Earlier, FDA cleared Acuvue Theravision with Ketotifen, illustrating a feasible path for ophthalmic combination devices. Payer recognition lowers out-of-pocket costs for chronic-disease patients, aligning incentives for wider prescription. EU payers are piloting similar codes under digital therapeutics frameworks, and Japan's universal coverage system is reviewing inclusion criteria. Reimbursement momentum accelerates volume adoption, particularly in diabetes care where continuous monitoring curbs long-term complications and associated costs.

Long-Term Biocompatibility of Stretchable Antennas Uncertain

Current ISO 10993 ocular protocols do not fully address nano-scale metal dissolution from serpentine silver-graphene traces used as antennas. Early 26-week rabbit trials revealed trace silver ion accumulation in retro-bulbar tissues, prompting the FDA to request multi-year follow-ups before approving continuous-wear indications. Manufacturers now explore biodegradable poly-L-lactic acid substrates and parylene-encapsulated interposers to curb leaching risks. Until long-term safety data matures, market penetration in chronic-use segments such as glaucoma and diabetes remains gated, restraining CAGR.

Other drivers and restraints analyzed in the detailed report include:

1. 5G/LTE-M eSIM Modules Enable Continuous Lens Connectivity
2. Silicon-Hydrogel Nanocomposites Slash Manufacturing Rejects
3. High BOM Keeps Low ASP per Lens in 2025

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Glucose-monitoring devices accounted for 58.55% of 2025 revenues, capitalizing on a diabetic population exceeding 540 million worldwide and the demonstrated clinical correlation between tear and blood glucose (R2 > 0.87 in recent human trials). Continuous glucose trackers reduce hypoglycemic events by 28% compared with finger-stick monitoring in a 180-day multi-center study, justifying payer coverage. Intraocular pressure monitoring serves 80 million glaucoma patients, enabling detection of nocturnal IOP spikes missed in clinic. Augmented reality overlays remain pre-commercial but fuel long-term upside as micro-LED efficiency improves.

Drug-delivery lenses, the fastest-growing application at 7.72% CAGR, employ vitamin E barriers or micro-reservoirs to sustain therapeutic dosing over days, addressing chronic adherence gaps in conditions like allergic conjunctivitis. FDA clearance of ketotifen-eluting lenses validates the regulatory pathway and spurs pipelines for prostaglandin analogs. The multi-functional lens archetype-diagnostic plus therapeutic-promises platform differentiation, reinforcing expansion of the smart contact lenses market.

Complete Report Scope:

• By Application
  • Ocular Monitoring & Glaucoma Treatment
  • Vision Impairment
• By End User
  • Hospitals & Ophthalmology Clinics
  • Home-care / Self-monitoring Consumers
  • Others (Academic Institutes, Rehabilitation Centers, among others)
• By Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Geography Analysis

North America maintained 58.54% smart contact lenses market share in 2025, underpinned by FDA clearances and robust reimbursement that cushion USD 300+ price points. The United States hosts production hubs for micro-LEDs and biosensors, anchoring supply chains and sparking university-industry consortia for ocular bioelectronics. Canada's single-payer system began pilot tear-glucose programs in 2025, broadening public coverage. Mexico leverages maquiladora incentives to attract lens assembly lines, compressing regional logistics cycles. Together, these dynamics preserve North America's leadership despite high labor costs.

Asia-Pacific delivers the fastest CAGR at 8.19%, buoyed by South Korea's expedited MFDS fast-track designations, Japan's AMED grants for bio-sensorization, and China's volume-driven component ecosystem. In China, a diabetic base of 141 million boosts demand for glucose lenses, while domestic display makers channel Mini-LED expertise into lens projects. India's Ayushman Bharat scheme begins covering remote IOP monitoring, activating rural demand. This confluence positions Asia-Pacific as the growth engine of the smart contact lenses market.

Europe records steady uptake as MDR clarity improves. Germany's DIGA framework now reimburses digital ophthalmic therapeutics, and France's Haute Autorite de Sante released 2025 guidelines for continuous ocular monitoring. United Kingdom spin-outs from University of Manchester advance graphene antennas compliant with NHS Cybersecurity Toolkit standards. Southern Europe and the Nordics pursue EU Structural Funds to equip regional hospitals with smart lens diagnostics. While CE-marking timelines extend launch cycles, Europe's emphasis on safety and data privacy cultivates user trust, reinforcing gradual but resilient adoption.

1. Innovega
2. SEED Co., Ltd. (Sensimed SA)
3. Smartlens, Inc.
4. Azalea Vision
5. InWith Corp
6. XPANCEO
7. Cylensee Inc.
8. BVS Sight Inc.
9. Samsung Group
10. Google LLC
11. Sony
12. PHI BIOMED

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Miniaturised on-lens biosensors reach sub-µW power levels
  • 4.2.2 Reimbursement codes emerging for IOP & glucose tear monitoring
  • 4.2.3 5 G / LTE-M eSIM modules enable continuous lens connectivity
  • 4.2.4 Silicon-hydrogel nanocomposites slash manufacturing rejects
  • 4.2.5 Pharma-device bundle deals for ocular drug-delivery lenses
  • 4.2.6 Big-Tech licensing of AR micro-display IP to lens makers
• 4.3 Market Restraints
  • 4.3.1 Long-term biocompatibility of stretchable antennas uncertain
  • 4.3.2 High BOM keeps ASP > US$300 per lens in 2025
  • 4.3.3 Fragmented global approval pathways (FDA, MDR, MFDS, NMPA)
  • 4.3.4 Supply of medical-grade micro-LEDs <5 µm remains constrained
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Application
  • 5.1.1 Ocular Monitoring & Glaucoma Treatment
  • 5.1.2 Vision Impairment
• 5.2 By End User
  • 5.2.1 Hospitals & Ophthalmology Clinics
  • 5.2.2 Home-care / Self-monitoring Consumers
  • 5.2.3 Others (Academic Institutes, Rehabilitation Centers, among others)
• 5.3 By Geography
  • 5.3.1 North America
  • 5.3.2 Europe
  • 5.3.3 Asia-Pacific
  • 5.3.4 Rest of the World

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Innovega
  • 6.3.2 SEED Co., Ltd. (Sensimed SA)
  • 6.3.3 Smartlens, Inc.
  • 6.3.4 Azalea Vision
  • 6.3.5 InWith Corp
  • 6.3.6 XPANCEO
  • 6.3.7 Cylensee Inc.
  • 6.3.8 BVS Sight Inc.
  • 6.3.9 Samsung Electronics Co Ltd
  • 6.3.10 Google LLC
  • 6.3.11 Sony Corporation
  • 6.3.12 PHI BIOMED

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment